Member Info for desamax

Off topic, I’m hearing Bill Gates is in London, wondering if he plans to visit Cambridge?

For 7p close.

Sheep, the old board also added two zeros to the MC
They chose to add them at the beginning shamefully. Well done all LTHs for sticking with Suzy we might be all smiles one day soon. Good luck everyone.

Hi S/D reading every snippet I can find. Timboo certainly knows his gravy, I’m not reg on there so can only read the headers. Trying to keep both feet on the ground. But we have all been anticipating this type of news. Let’s hope it’s also as fruitful as anticipated.

To see if any of our resident boffs have dissected the info. But trying to be patient. Lol.

Wishing you both all the very best for a speedy recovery, just in time to enjoy your spoils from SAR.

Some more here sorry if repost
https://cancerres.aacrjournals.org/content/80/16_Supplement/LB-121

Getting lots of press coverage today,

https://www.theguardian.com/science/2021/oct/13/drug-trial-offers-new-hope-for-those-with-metastatic-breast-cancer

http://www.sareum.com/news/press-releases-and-news/2017/sierra-oncology-host-call-chk1-inhibitor1/

should get a response to the below amend request very soon as it’s been updated today to “ Awaiting classification. “……….
We're waiting for Rob Zimmerman to read a recent response and update the status.”……..

“ Dear UK Research and Innovation,

Thank you for your response.
As suggested, I wish to amend the original request to limit the information required to:
1) copy of the final outturn report, including recommendations.
2) details of any further planned potential follow-on studies involving UKRI in respect of SDC-1801.

Yours faithfully,

Rob Zimmerman“

Can anyone brake this down into laymans terms, where does sra737 come into this & what’s it mean?
Will the bod put this down to srra.
Thanks

Thanks Qwai,
So they retweeted without adding any comments.
Glad to see the tweets tho.

Has there been any tweets from Parker or SAR or anyone linked to the company? They’re normally tweeting as the news drops or when prompted by our army. Strange silence on the latest announcement. Hmmmmmmm

Taken from last year, this is where we’re heading….

The patent will protect the SDC-1802 molecule and its pharmaceutical preparation.

SDC-1802 is a dual tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor. TYK2 and JAK1 are members of the Janus Kinase (JAK) family of protein kinase enzymes that play roles in autoimmune diseases and tumour cell proliferation in cancer.

In statement, Dr John Reader, Sareum's chief scientific officer, said: "The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets.

“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company's negotiating position as it continues to engage in discussions with potential licence partners."

Smart, glad to hear your not a doom monger, if you look at the pattern of the last week and beyond, wombles have popped up trying to influence weak Holders.
GLA.

As seems to happen before every announcement.
Let’s focus on the positive as all holder’s are in this together, if a womble gets a sniff of anyone uncertain they will pounce.

Not so smart inv.
Remind us what the SP was 6 & 12 months ago?
I’m sure that’s part of the pattern from . 3 of a penny upwards, don’t you agree?

Notalot, Wishing you all the very best and a speedy recovery,

This is just the start.

FINAL RESULTS FOR THE YEAR ENDED 30 JUNE Also due soon.

If you bought the Tee shirt this time last year or even. 6 mths ago, it would still be in it wrapper and gained value.

Robs reply ….

Rob Zimmerman 1 October 2021
Delivered
Dear UK Research and Innovation,

Thank you for your response.
As suggested, I wish to amend the original request to limit the information required to:
1) copy of the final outturn report, including recommendations.
2) details of any further planned potential follow-on studies involving UKRI in respect of SDC-1801.

Yours faithfully,

Rob Zimmerman